Acquisition will strengthen MYND’s psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the treatment of dementia, including Alzheimer’s disease. VANCOUVER, BC, Oct. 27, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND“) (CSE: MYND) (OTC: MYNDF) is pleased to announce it has entered into an agreement to acquire the right, title and interest in and to the…
